LifeServe Innovations, LLC is bridging the gap between academia and medicine to develop high impact medical technologies for critical care and oxygen delivery. Our products set a higher standard for innovation in medicine by improving health-care for our patients and their providers.
Website: http://www.lifeserveinnovations.com
LifeMedix, LLC is developing a hand-held, ultra-portable medical infusion pump. Generating its own electricity in conjunction with a piezoelectric component and battery, the device requires no external electrical power source or battery recharging. Although it will primarily be used by paramedics or military medics in a pre-hospital setting for patients requiring prompt intravenous fluid resuscitation, it can also be used in operating rooms, emergency departments, and on code-carts for immediate fluid or medication resuscitation.
Designed to bolus and titrate the rate of I.V. fluid infusion, the pump is applicable to a variety of patient needs. The device may be used for shock resuscitation, intravenous fluid infusion, wound irrigation, blood transfusions, traumatic brain injury and medication administration.
An additional cartridge that facilitates negative-pressure wound (wound vac) is in the innovation pipeline.
Website: http://www.lifemedix.com
LARAD, Inc. is using virus-like particle technology to produce universal multivalent vaccines and diagnostics for food-animal diseases. The company's initial focus is on products licensed from The Ohio State University for an immunosuppressive disease in poultry caused by the infectious bursal disease virus. Its genetically engineered universal vaccine can protect against multiple strains of the virus and its flexibility allows new antigens to easily be introduced, allowing it to keep pace with new antigenic changes in the virus.
The company received a $25,000 Innovation Fund A award in May 2013 and the $100,000 B award in August 2014.
Website: https://www.laradinc.com/
We are a spinoff of University Hospitals Case Medical Center commercializing photodynamic therapy for the treatment of psoriasis and other skin diseases. Researchers at University Hospitals Case Medical Center and Case Western Reserve University have over many years developed, patented and conducted Phase I clinical trials on a photosensitizer known as Pc 4. Pc 4 is a silicon phthalocyanine which, when excited by visible light, attacks tumor cells, abnormal vasculature, and other lipophilic sites and has a number of advantages over other photosensitizers.
Website: http://www.fluencetherapeutics.com
Environmental Fracturing Solutions, Inc. has developed a variant formulation of their parent company’s technology to provide a safe and cost-effective method to treat the water used in the fracking industry. The proprietary and patent pending technology platform provides a biocide /bio-static product that concentrates ions in their optimal antimicrobial state in solution. It is stable, easy to use and is EPA certified class IV, virtually harmless to handle.
The company received the Innovation Fund's A award in August 2013 and its B award in February 2014.
Endotronix, Inc. is a medical device company dedicated to wireless health monitoring for congestive heart failure (CHF) patients. The company is developing miniaturized, wireless pressure sensors that are implanted as part of interventional cardiovascular procedures and interface to an external measurement instrument.
Endotronix's "Anytime, Anywhere" wireless sensing platform technology will provide long term patient data and give physicians the ability to dramatically reduce the occurrence of CHF-related events and hospitalizations by remotely monitoring a patient's health status and titrating medications appropriately to prevent worsening heart function.
Website: https://endotronix.com/
Disease Diagnotstic Group, LLC (DDG) is commercializing the Rapid Assessment of Malaria (RAM) device to provide a full solution to the malaria diagnostic, treatment, and tracking space.
Founded in August 2012, the social venture has patented a mechanical approach to diagnosis by manipulating the magnetic malaria hemozoin to attenuate light. Having deployed prototypes to Peru and India for clinical testing, DDG is seeking product approval for commercialization in 2014. DDG expects to steadily capture market share, ultimately becoming the worldwide standard for point of care malaria diagnosis.
John Lewandowski (CEO/Founder) holds an MBA from CWRU and Dr. Brian T. Grimberg (CMO/President) is a malaria expert, the original inventor, and an assistant professor in the Center for Global Health and Infectious Disease at CWRU.
DDG received an Innovation Fund A grant in August 2013.
Website: http://www.diseasediagnostic.com/
Centerline Biomedical is a Cleveland Clinic spin-off company developing a surgical navigation system for physicians performing endovascular procedures. Centerline’s technology reduces the amount of harmful radiation associated with these procedures, increases accuracy for better clinical outcomes, and will lower costs associated with these procedures.
The company received a $100,000 Innovation Fund B award in February 2015.
BioMendics, LLC is a wound healing technology company using liquid crystalline biomimetics for the treatment of chronic wounds. This proprietary platform technology creates a partially ordered film across the surface of the skin while mimicking growth factors to target all phases of the wound healing process. The technology accelerates wound closure while providing a safe, cost effective & easy to use consumer product.
The company received the $25,000 Innovation Fund award in December 2014 and is using the funds for additional patent protection, chemical synthesis and experiments toward FDA approval.
Website: https://www.biomendics.com/
Biolectrics combines medical, biological, and electrical research to develop a pioneering new treatment for severe gum disease with a family of oral care devices called the OraFlow™.
Website: http://biolectrics.net/